Trial Profile

A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythematosus

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary) ; Rituximab (Primary) ; Methylprednisolone; Mycophenolate mofetil; Prednisolone
Indications Systemic lupus erythematosus
Focus Proof of concept; Therapeutic Use
Acronyms SynBioSe-2

Most Recent Events

17 Oct 2024 Planned End Date changed from 1 Sep 2025 to 7 Jun 2026.
17 Oct 2024 Status changed from recruiting to active, no longer recruiting.
05 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com